Vaccine manufacturer AstraZeneca acknowledged that thrombocytopenia syndrome (TSS) is a rare risk associated with its COVID-19 vaccine in court documents from an ongoing lawsuit in the U.K. This story has received widespread coverage on conspiracy and tabloid sites where it is misleadingly framed as a “bombshell” admission because this is the first time the company has acknowledged the adverse reaction in court, despite TTS being a known rare risk of both the Astra Zeneca and Johnson & Johnson COVID-19 vaccines since 2021.
Recommendation: 
Sign Up for Public Health Alerts
About Us
The Public Health Communications Collaborative (PHCC) was formed in 2020 to coordinate and amplify public health messaging on COVID-19 and increase Americans’ confidence in guidance from the Centers for Disease Control and Prevention (CDC) and state and local public health officials.
Learn More
Learn More